Table 1.
Characteristics of lung cancer patients stratified by histological type.
| SCLC N = 197 | NSCLCN = 207 | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Alive 89 (45.18%) | Dead 108 (54.82%) | Total | P-value | Alive 102 (49.28%) | Dead 105 (50.72%) | Total | P-value | ||
| Age at diagnosis, mean (SD) | 62.39 (SD 13.26) | 66.04 (SD 11.30) | 64.39(SD 12.33) | 0.04 * | 61.42 (SD 12.09) | 62.94(SD 12.94) | 62.19(SD 12.52) | 0.3833* | |
| Sex | Male | 73 (42.69%) | 98 (57.31%) | 171 (86.80%) | 0.07** | 79 (77.45%) | 87 (82.86%) | 166 (80.19%) | 0.329** |
| Female | 16 (61.54%) | 10 (38.46%) | 26 (13.20%) | 23 (22.55%) | 18 (17.14%) | 41 (19.81%) | |||
| Year of diagnosis | 2009 | 16 (17.98%) | 21 (19.44%) | 37 (18.78%) | 0.433 ** | 29 (28.43%) | 30 (28.57%) | 59 (28.5%) | 0.025** |
| 2010 | 19 (21.35%) | 28 (25.93%) | 47 (23.86%) | 22 (21.57%) | 22 (20.95%) | 44 (21.26%) | |||
| 2011 | 17 (19.10%) | 19 (17.59%) | 36 (18.27%) | 9 (8.82%) | 22 (20.95%) | 31 (14.98%) | |||
| 2012 | 14 (15.73%) | 23 (21.30%) | 37 (18.78%) | 17 (16.67%) | 20 (19.05%) | 37 (17.87%) | |||
| 2013 | 23 (25.84%) | 17 (15.74%) | 47 (20.30%) | 25 (24.51%) | 11 (10.48%) | 36 (17.39%) | |||
| Topography | Main Bronchus | 7 (7.87%) | 12 (11.11%) | 19 (9.64%) | 0.597*** | 6 (5.88%) | 4 (3.81%) | 10 (4.83%) | 0.851*** |
| Upper lobe | 24 (26.97%) | 27 (25%) | 51 (25.89%) | 33 (32.35%) | 34 (32.38%) | 67 (32.37%) | |||
| Middle lobe | 4 (4.49%) | 5 (4.63%) | 9 (4.57%) | 3 (2.94%) | 6 (5.71%) | 9 (4.35%) | |||
| Lower lobe | 19 (21.35%) | 14 (12.96%) | 33 (16.75%) | 21 (20.59%) | 20 (19.05%) | 41 (19.81%) | |||
| Overlapped lesion | 3 (3.37%) | 7 (6.48%) | 10 (5.08%) | 5 (4.90%) | 3 (2.86%) | 8 (3.86%) | |||
| Not otherwise specified | 32 (35.96%) | 43 (39.81%) | 75 (38.07%) | 34 (33.33) | 38 (36.19%) | 72 (34.78%) | |||
| Carcinoma Of other ill-defined sites | 0 | 0 | 0 | 0 | 0 | 0 | |||
| Stage | Localized | 16 (17.98%) | 6 (5.56%) | 22 (11.17) | 16 (15.69%) | 7 (6.67%) | 23 (11.11%) | ||
| Regional by direct extension | 7 (7.87%) | 2 (1.85%) | 9 (4.54%) | 7 (6.86%) | 3 (2.86%) | 10 (4.83%) | |||
| Regional by lymph node | 6 (6.74%) | 4 (3.7%) | 10 (5.08%) | 7 (6.86%) | 2 (1.9%) | 9 (4.35%) | |||
| Regional by both direct extension and lymph node | 4 (4.49%) | 5 (4.63%) | 9 (4.57%) | 2 (1.96%) | 2 (1.9%) | 4 (1.93%) | |||
| Regional-NOS | 0 | 1 (0.93%) | 1 (0.51%) | 1 (0.98%) | 1 (0.95%) | 2 (0.97%) | |||
| Distance metastasis/Systematic disease | 56 (62.92) | 90 (83.33% | 146 (74.11) | 69 (67.65%) | 90 (85.71%) | 159 (76.81%) | |||
| Laterality | Not paired | 1 (1.12%) | 1 (0.93%) | 2 (1.02%) | 0.876 *** | 0 | 0 | 0 | 0.453*** |
| Right origin | 44 (49.44%) | 51 (47.22%) | 95 (48.22%) | 57 (55.88%) | 64 (60.95%) | 121 (58.45%) | |||
| Left origin | 32 (35.96%) | 35 (32.41%) | 67 (34.01%) | 34 (33.33%) | 32 (30.48%) | 66 (31.88%) | |||
| Only one side involved (right or left) unspecified | 0 | 0 | 0 | 6 (5.88%) | 2 (1.90%) | 8 (3.86%) | |||
| Bilateral (side of origin unknown or single primary) | 2 (2.25%) | 4(3.70%) | 6 (3.05%) | 5 (4.90%) | 7 (6.67%) | 12 (5.80%) | |||
| Midline origin | 0 | 0 | 0 | 0 | 0 | 0 | |||
| paired no information concerning laterality | 10 (11.24%) | 17 (15.74%) | 27 (13.71%) | 0 | 0 | 0 | |||
*
T-test
**
Chi-square test
***
Fisher’s exact test.